- Home
- JZXN vs IXHL Comparison
JZXN vs IXHL Comparison
Compare JZXN & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- IXHL
- Stock Information
- Founded
- JZXN 2017
- IXHL 2001
- Country
- JZXN China
- IXHL Australia
- Employees
- JZXN 33
- IXHL N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- IXHL
- Sector
- JZXN Consumer Discretionary
- IXHL
- Exchange
- JZXN Nasdaq
- IXHL Nasdaq
- Market Cap
- JZXN 45.5M
- IXHL 39.2M
- IPO Year
- JZXN 2021
- IXHL N/A
- Fundamental
- Price
- JZXN $4.37
- IXHL $1.61
- Analyst Decision
- JZXN
- IXHL
- Analyst Count
- JZXN 0
- IXHL 0
- Target Price
- JZXN N/A
- IXHL N/A
- AVG Volume (30 Days)
- JZXN 170.6K
- IXHL 50.3K
- Earning Date
- JZXN 09-09-2024
- IXHL 02-14-2025
- Dividend Yield
- JZXN N/A
- IXHL N/A
- EPS Growth
- JZXN N/A
- IXHL N/A
- EPS
- JZXN N/A
- IXHL N/A
- Revenue
- JZXN $7,597,423.00
- IXHL $98,000.00
- Revenue This Year
- JZXN N/A
- IXHL $3,817.06
- Revenue Next Year
- JZXN N/A
- IXHL $66.67
- P/E Ratio
- JZXN N/A
- IXHL N/A
- Revenue Growth
- JZXN 81.94
- IXHL N/A
- 52 Week Low
- JZXN $1.00
- IXHL $1.50
- 52 Week High
- JZXN $67.60
- IXHL $8.47
- Technical
- Relative Strength Index (RSI)
- JZXN 70.40
- IXHL 40.02
- Support Level
- JZXN $3.53
- IXHL $1.54
- Resistance Level
- JZXN $6.46
- IXHL $1.88
- Average True Range (ATR)
- JZXN 0.74
- IXHL 0.15
- MACD
- JZXN 0.17
- IXHL -0.03
- Stochastic Oscillator
- JZXN 55.05
- IXHL 9.99
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.